The systematic review initially resulted in 98 publications related to the epigenetic target Enhancer Of Zeste 2 Polycomb Repressive Complex 2 Subunit (EZH2), 6 related to Bromodomain Containing 4 (BRD4), 5 related to Protein Arginine Methyltransferase 1 (PRMT1), 4 related to each Lysine Demethylase 6B (KDM6B) and Bromodomain Containing 9 (BRD9) targets; one related to Coactivator Associated Arginine Methyltransferase 1 (CARM1), and no work related to Bromodomain Adjacent To Zinc Finger Domain 2 (BAZ2A) or Peptidyl Arginine Deiminase 4 (PADI4) as targets in lung cancer. Here, EZH2 is linked to lung cancer.